Information Provided By: 
Fly News Breaks for June 26, 2017
AGIO
Jun 26, 2017 | 07:39 EDT
As previously reported, Janney Capital analyst Debjit Chattopadhyay downgraded Agios Pharmaceuticals to Neutral from Buy as he believes peak sales estimates for its acute myeloid leukemia treatment are likely to move lower over time. The company's clinical update on AG348 at the EHA meeting was "generally consistent with prior disclosures on efficacy" but with some new serious adverse events, Chattopadhyay also noted. He maintains a $57 fair value estimate on Agios shares.
News For AGIO From the Last 2 Days
There are no results for your query AGIO
